Navigation Links
Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
Date:11/1/2010

//Newsrelease id s.tl(this,'o', 'CrowdFactory_'+socialText);*/ var s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15,prop16,prop49,events';s.linkTrackEvents='event12';s.prop5='share it release';s.eVar3=s.prop5; s.prop15='106439393';s.prop16='CrowdFactory_'+socialText;s.prop5+='_'+s.prop16;s.prop49=s.pageName;s.events='event12';s.tl(this,'o','CrowdFactory_'+socialText); }); });  

ABBOTT PARK, Ill. and WATERTOWN, Mass., Nov. 1, 2010 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Enanta Pharmaceuticals today announced positive results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C (HCV) infection.  Initial 3-day and 4-week results suggest that ABT-450/r (ABT-450 with 100mg of ritonavir to support once-daily dosing) demonstrates potent antiviral activity in treatment-naïve adults.  Results show that more than 90 percent of patients (21 of 23) on study drug achieved HCV-RNA levels <25 IU/mL at four weeks. Results were presented today at the American Association for the Study of Liver Disease annual meeting in Boston.

Key findings:  

  • After three days, treatment with ABT-450/r alone resulted in statistically significant, 4-log mean reductions of HCV RNA, across the three dose ranges of ABT-450 (50mg, 100mg, 200mg, once-daily dosing) compared to placebo  
  • At week four, 91.3 percent (21 of 23) of patients receiving ABT-450/r in combination with standard of care (SOC) – pegylated alpha interferon and ribavirin (pegIFN/RBV) – achieved HCV-RNA <25 IU/ml
  • Safety appears consistent to that expected with SOC

  • "In spite of the progress that has been made in HCV treatment, limitations in efficacy remain with the current standard of care," Fred Poordad, M.D., chief of hepatology at the Liver Disease and Transplant
    '/>"/>

    SOURCE Abbott
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Abbott Again Recognized for Environmental Initiatives in Illinois
    2. Abbott Statement: Abbott Provides Support for Cholera Relief Efforts in Haiti
    3. Abbott to Voluntarily Withdraw Meridia® (Sibutramine) in the U.S.
    4. Abbott Laboratories Agrees to Withdraw Its Obesity Drug Meridia
    5. Abbott Named One of the Top Employers in the Biotech and Pharmaceutical Industry by Science Magazine
    6. Abbott Receives FDA Market Clearance for Next-Generation Contact Lens Disinfecting Solution
    7. Abbotts XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
    8. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
    9. Abbotts Fully Bioresorbable Vascular Scaffold Technology Continues to Demonstrate Strong Clinical Results
    10. The Deal Names Abbott Top Dealmaker for Third Consecutive Year
    11. Abbott Declares 347th Consecutive Quarterly Dividend
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)... SAN FRANCISCO , Aug. 31, 2015  On ... District of Oregon denied motions ... Inc. (NASDAQ: GALE ) and certain of its ... had facilitated a "pump and dump" scheme to artificially ... trading period while the stock price was inflated, sold ...
    (Date:8/31/2015)... 31, 2015  Regulatory affairs professionals work at ... are often strict and legislation is ever-changing. The ... for professionals who have a deep understanding of ... product lifecycle and demonstrate its use across various ... California, Irvine Extension , in partnership with the ...
    (Date:8/31/2015)... Aug. 31, 2015 Regen BioPharma, Inc. (OTCBB: ... a novel means of delivering its patented (US ... liver tumors utilizing a clinically approved formulation as ... hurdles with gene silencing therapeutics in which the ... the whole body.  By utilizing a local delivery ...
    Breaking Medicine Technology:Galena Biopharma, Inc. Stock Alert: Schubert Firm Investigates Potential Breaches of Fiduciary Duty 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
    ... Ore.--(BUSINESS WIRE)--Jul 10, 2007 - AVI BioPharma, Inc.,(Nasdaq:AVII) ... target patient enrollment and released six-month,follow-up data from ... trial, currently being held in Germany, was designed ... Resten-MP(TM), when,used in conjunction with the placement of ...
    ... Fail to Demonstrate Meaningful Placebo Adjusted Weight,Loss; ... July 09, 2007 /PRNewswire-FirstCall/ -- Manhattan,Pharmaceuticals, Inc. ... 2a clinical trials of oral Oleoyl-estrone (OE). ... one,in common obesity and the other in ...
    Cached Medicine Technology:AVI BioPharma Partner Cook Medical Announces Completion of Patient,Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of,Cardiovascular Disease 2Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 2Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 3Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 4
    (Date:9/1/2015)... ... September 01, 2015 , ... Elizabeth Callahan, MD, founder and medical director of ... area to offer RADIESSE® filler treatment for volume loss in the hands. RADIESSE provides ... veins in the hands, delivering smooth, natural-looking results that can last up to one ...
    (Date:9/1/2015)... ... ... A new episode of “Voices In America”, hosted by famous actor and voice over ... are over 100 different types of arthritis. One of the most popular is rheumatoid ... shed light on this important topic. , Anyone who is nearing their golden years ...
    (Date:9/1/2015)... , ... September 01, 2015 , ... ... availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol ... protocols to understand the scope of their EHS regulatory obligations and rapidly collect, ...
    (Date:8/31/2015)... ... 2015 , ... AthleticTraining.com, provider of CEUs for athletic trainers ... premium on-demand video Evidence Based Practice courses that meet the ... complete 50 CEUs before December 31, 2015, which must include at least 10 ...
    (Date:8/31/2015)... ... August 31, 2015 , ... Jvion, the Atlanta-based leader in ... case focused on helping hospital perform under the Center for Medicare & Medicaid ... adjusted based on performance across four domains related to care quality. To receive ...
    Breaking Medicine News(10 mins):Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 2Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 3Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 4Health News:Evidence Based Practice Courses: CEUs For Athletic Trainers Just Released 2Health News:Jvion Releases Value-Based Purchasing Predictive Use Case 2
    ... More than 7,000 leaders,in academic pediatrics will ... meeting of the Pediatric Academic Societies (PAS), the,American ... Pediatric,Research. The site is the Hawai,i Convention Center ... be the world,s largest academic pediatrics meeting as,practitioners ...
    ... change afoot in the way medicine is being taught. ... demanding clinical training are necessarily at the forefront. To ... future physicians, a movement is growing determined to ... who are also compassionate individuals able to communicate well ...
    ... Sponsor of the Cycling Event for the,5th Consecutive Year, ... SCOOTER Store, America,s leading supplier of power wheelchairs and,scooters, ... National Multiple,Sclerosis Society by participating in the MS150 bike ... as a Platinum Sponsor of,the two-day cycling journey from ...
    ... Board of Directors, SAN JOSE, Calif., April ... home improvement retailer, today announced a,partnership with Canary ... the funding, discovery and development of,tests for early ... OSH has been appointed to Canary Foundation,s Board ...
    ... declines have hit a plateau, report says , , TUESDAY, ... seem to have stagnated, a new report shows, as ... recent declines appear to have leveled off. , "We,ve ... getting necessary screening. The next big barrier is the ...
    ... than halved in the Tyrol after a programme was introduced ... to research published in April issue of the urology journal ... of eligible men have been tested at least once since ... had fallen by 54 per cent, compared with 29 per ...
    Cached Medicine News:Health News:Developing 'roadmaps' for enhancing the professional culture of medical schools 2Health News:The SCOOTER Store and Their Employees Contribute $43,000 in MS150 Bike Ride to Help Texans With Multiple Sclerosis 2Health News:Orchard Supply Hardware Partners With Canary Foundation 2Health News:Orchard Supply Hardware Partners With Canary Foundation 3Health News:Cancer Death Rates Stay Stagnant 2Health News:Cancer Death Rates Stay Stagnant 3Health News:Prostate cancer screening program leads to bigger fall in death rates than surrounding areas 2Health News:Prostate cancer screening program leads to bigger fall in death rates than surrounding areas 3
    Open blade design with aspiration capabilities for removing fluids from the operative site. 19 gauge wire....
    Designed to provide open approaches of the keratome to the cornea for either the left or right eye. Lightweight wire design adds to the comfort of the instrument when in place....
    Solid 14 mm free-swinging blades, suture posts, and stabilizing disk. Dull finish....
    Designed for use with foster enucleation snare (E3670). Package of 12 stainless steel wires. Overall length 5.3 inches....
    Medicine Products: